Therapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review

Skrócona strona pozycji
dc.contributor.authorVityala, Srilaxmi
dc.contributor.authorKanteti, Krishna Priya
dc.contributor.authorVityala, Yethindra
dc.contributor.authorTagaev, Tugolbai
dc.contributor.authorDamineni, Ujwala
dc.date.accessioned2024-03-29T19:55:19Z
dc.date.available2024-03-29T19:55:19Z
dc.date.issued2024-03
dc.description.abstractIntroduction and aim. In patients with schizophrenia, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) treatment was found to ameliorate the cardiovascular, metabolic, and inflammatory problems caused by antipsychotic medication and even reduce the need for medication by 20%. In this study, we evaluated the potential therapeutic effects of n-3 PUFA supplementation in patients with schizophrenia. Material and methods. The PRISMA guidelines were followed in conducting this systematic review. The Embase, MEDLINE, Web of Science, and Google Scholar databases were searched electronically. The first search yielded 50 papers in total. Subse quently, 43 publications that did not meet our eligibility requirements were removed, and seven articles were selected. Analysis of the literature. The analysis showed that n-3 PUFA supplementation and the placebo group both decreased their psychotic (PANSS and GAF scales) and Calgary Depression Scale symptomatology and boosted their functional ability (GAF) when used as an adjuvant to antipsychotic medication. When administered as a monotherapy with a metabolic antioxidant, n-3 PUFA supplementation proved beneficial for treating schizophrenia. In patients with schizophrenia, n-3 PUFAs have thera peutic benefits as adjuvant treatments to medications, although not for different variables or patient groups. Conclusion. In many studies, patients with chronic schizophrenia who received n-3 PUFA supplementation showed no improvement in their clinical condition.eng
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 22, z. 1 (2024), s. 172–178
dc.identifier.doi10.15584/ejcem.2024.1.5
dc.identifier.eissn2544-1361
dc.identifier.urihttps://repozytorium.ur.edu.pl/handle/item/10373
dc.language.isoeng
dc.publisherPublishing Office of the University of Rzeszow
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Poland*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/pl/*
dc.subjectdocosahexaenoic acid
dc.subjecteicosapentaenoic acid
dc.subjectomega-3 polyunsaturated fatty acids
dc.subjectschizophrenia
dc.subjectsupplementation
dc.titleTherapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review
dc.typearticle
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
23.therapeutic_advantages_of_omega-3_fatty_acid_supplementation.pdf
Rozmiar:
249.83 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.28 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.22, z. 1 (2024)